Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/in-vitro-assessment-of-nucleoside-analogs-in-multiple-myeloma-aFcaS8GfmS
References (49)
-
W. Parker, Y. Cheng (1987)
Inhibition of DNA primase by nucleoside triphosphates and their arabinofuranosyl analogs.Molecular pharmacology, 31 2
-
M. Oken (1992)
New agents for the treatment of multiple myeloma and non-Hodgkin lymphoma.Cancer, 70 4 Suppl
-
A. Jemal, Taylor Murray, A. Samuels, Asma Ghafoor, Elizabeth Ward, M. Thun (2003)
Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 53
-
Y. Gazitt, M. Rothenberg, Susan Hilsenbeck, V. Fey, Charles Thomas, W. Montegomrey (1998)
Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells.International journal of oncology, 13 4
-
Varsha Gandhi, W. Plunkett (1990)
Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides.Cancer research, 50 12
-
L. Wang, A. Karlsson, Elias Arnér, S. Eriksson (1993)
Substrate specificity of mitochondrial 2'-deoxyguanosine kinase. Efficient phosphorylation of 2-chlorodeoxyadenosine.The Journal of biological chemistry, 268 30
-
H. Kantarjian, R. Dreicer, B. Barlogie, W. Plunkett, R. Alexanian (1984)
High-dose cytosine arabinoside in multiple myeloma.European journal of cancer & clinical oncology, 20 2
-
T. Spasokoukotskaja, Elias Arnér, O. Brosjö, P. Gunvén, G. Juliusson, J. Liliemark, S. Eriksson (1995)
Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissues.European journal of cancer, 31A 2
-
RA Nagourney, S. Evans, JC Messenger, YZ Su, LM Weisenthal (1993)
2 chlorodeoxyadenosine activity and cross resistance patterns in primary cultures of human hematologic neoplasms.British Journal of Cancer, 67
-
P. Huang, S. Chubb, S. Chubb, L. Hertel, G. Grindey, W. Plunkett (1991)
Action of 2',2'-difluorodeoxycytidine on DNA synthesis.Cancer research, 51 22
-
W. Plunkett, V. Gandhi (2001)
Purine and pyrimidine nucleoside analogs.Cancer chemotherapy and biological response modifiers, 19
-
E. Kraut, J. Crowley, M. Grever, M. Keppen, J. Bonnet, H. Hynes, S. Salmon (1990)
Phase II study of Fludarabine Phosphate in multiple myelomaInvestigational New Drugs, 8
-
J. Weick, J. Crowley, M. Hussein, D. Moore, B. Barlogie (2002)
The Evaluation of Gemcitabine in Resistant or Relapsing Multiple Myeloma, Phase II: a Southwest Oncology Group StudyInvestigational New Drugs, 20
-
R. Alexanian, M. Dimopoulos (1994)
The treatment of multiple myeloma.The New England journal of medicine, 330 7
-
C. Lambe, D. Averett, Melanie Paff, John Reardon, Joan Wilson, T. Krenitsky (1995)
2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies.Cancer research, 55 15
-
O. Hjertner, M. Börset, A. Waage (1996)
Comparison of the effects of 2-chlorodeoxyadenosine and melphalan myeloma cell lines.Leukemia research, 20 2
-
S. Lichtman, A. Mittelman, D. Budman, C. Puccio, H. Chun, S. Allen, T. Ahmed, Z. Arlin (1991)
Phase II Trial of Fludarabine Phosphate in Multiple Myeloma Using a Loading Dose and Continuous Infusion Schedule.Leukemia & lymphoma, 6 1
-
Chunxi Xie, W. Plunkett (1995)
Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)-adenine in human lymphoblastoid cells.Cancer research, 55 13
-
(2001)
Combination strategies for purine nucleoside analogs -
V. Gandhi, J. Legha, F. Chen, L. Hertel, W. Plunkett (1996)
Excision of 2',2'-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA.Cancer research, 56 19
-
Ralf Grunewald, H. Kantarjian, Michael Keating, J. Abbruzzese, Peter Tarassoff, W. Plunkett (1990)
Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia.Cancer research, 50 21
-
D. Shewach, K. Reynolds, L. Hertel (1992)
Nucleotide specificity of human deoxycytidine kinase.Molecular pharmacology, 42 3
-
(2000)
A phase I - II clinical trial with a combination of gemcitabine and paclitaxel for the treatment of refractory multiple myeloma patients ( abstract no . 4984 ) -
Volker Heinemann, Y. Xu, S. Chubb, Alina Sen, L. Hertel, G. Grindey, W. Plunkett (1990)
Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine.Molecular pharmacology, 38 4
-
R. Goldman-Leikin, H. Salwen, C. Herst, D. Variakojis, M. Bian, M. Beau, P. Selvanayagan, R. Marder, R. Anderson, S. Weitzman (1989)
Characterization of a novel myeloma cell line, MM.1.The Journal of laboratory and clinical medicine, 113 3
-
D. Ives, Sue-May Wang (1978)
[43] Deoxycytidine kinase from calf thymusMethods in Enzymology, 51
-
P. Moalli, S. Pillay, Dawn Weiner, Robin Leikin, Steven Rosen (1992)
A mechanism of resistance to glucocorticoids in multiple myeloma: transient expression of a truncated glucocorticoid receptor mRNA.Blood, 79 1
-
C. Rodriguez, B. Mitchell, M. Ayres, S. Eriksson, V. Gandhi (2002)
Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase.Cancer research, 62 11
-
Birthe Lund, P. Kristjansen, Heine Hansen (1993)
Clinical and preclinical activity of 2',2'-difluorodeoxycytidine (gemcitabine).Cancer treatment reviews, 19 1
-
J. Gruber, F. Geisen, R. Sgonc, A. Egle, A. Villunger, G. Boeck, G. Konwalinka, R. Greil (1996)
2′,2′‐Difluorodeoxycytidine (Gemcitabine) Induces Apoptosis in Myeloma Cell Lines Resistant to Steroids and 2‐Chlorodeoxyadenosine (2‐CdA)STEM CELLS, 14
-
Y. Gazitt, G. Roodman, C. Freytes, P. Shaughnessy, N. Callander, A. Traynor, M. Rothenberg (2000)
A phase I-II clinical trial with a combination of gemcitabine (GEMZAR) and paclitaxel (TAXOL) for the treatment of refractory multiple myeloma (MM) patientsBlood, 96
-
M. Attal, J. Harousseau, A. Stoppa, J. Sotto, J. Fuzibet, J. Rossi, P. Casassus, H. Maisonneuve, T. Facon, N. Ifrah, C. Payen, R. Bataille (1996)
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaThe New England Journal of Medicine, 335
-
W. Plunkett, Pearl Huang, C. Searcy, V. Gandhi (1996)
Gemcitabine: preclinical pharmacology and mechanisms of action.Seminars in oncology, 23 5 Suppl 10
-
L. Hertel, G. Boder, J. Kroin, S. Rinzel, G. Poore, G. Todd, G. Grindey (1990)
Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).Cancer research, 50 14
-
B. Braakhuis, G. Dongen, J. Vermorken, G. Snow (1991)
Preclinical in vivo activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer.Cancer research, 51 1
-
T. Krenitsky, J. Tuttle, G. Koszalka, I. Chen, L. Beacham, J. Rideout, G. Elion (1976)
Deoxycytidine kinase from calf thymus. Substrate and inhibitor specificity.The Journal of biological chemistry, 251 13
-
C. Baker, J. Banzon, J. Bollinger, J. Stubbe, V. Samano, Morris Robins, B. Lippert, E. Jarvi, R. Resvick (1991)
2'-Deoxy-2'-methylenecytidine and 2'-deoxy-2',2'-difluorocytidine 5'-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase.Journal of medicinal chemistry, 34 6
-
N. Krett, J. Zell, R. Halgren, S. Pillay, A. Traynor, S. Rosen (1997)
Cyclic adenosine-3',5'-monophosphate-mediated cytotoxicity in steroid sensitive and resistant myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research, 3 10
-
W. Bellamy, W. Dalton, Mary Gleason, T. Grogan, J. Trent (1991)
Development and characterization of a melphalan-resistant human multiple myeloma cell line.Cancer research, 51 3
-
W. Plunkett, P. Huang, Y. Xu, V. Heinemann, R. Grunewald, V. Gandhi (1995)
Gemcitabine: metabolism, mechanisms of action, and self-potentiation.Seminars in oncology, 22 4 Suppl 11
-
C. Nabhan, D. Gajria, N. Krett, V. Gandhi, K. Ghias, S. Rosen (2002)
Caspase activation is required for gemcitabine activity in multiple myeloma cell lines.Molecular cancer therapeutics, 1 13
-
Roger Lewis, L. Link (1989)
Phosphorylation of arabinosyl guanine by a mitochondrial enzyme of bovine liver.Biochemical pharmacology, 38 12
-
V. Gandhi, L. Danhauser, W. Plunkett (1987)
Separation of 1-β-d-arabinofuranosylcytosine 5′-triphosphate and 9-β-d-arabinofuranosyl-2-fluoroadenine 5′-triphosphate in human leukemia cells by high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 413
-
(2003)
Gemcitabine is a potent inducer of apoptosis in multiple myeloma cells in vitro and has synergistic effects with modulators of protein kinase -
Volker Heinemann, L. Hertel, G. Grindey, W. Plunkett (1988)
Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine.Cancer research, 48 14
-
M. Tempero, W. Plunkett, V. Haperen, J. Hainsworth, H. Hochster, R. Lenzi, J. Abbruzzese (2003)
Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 18
-
M. Offidani, A. Mele, L. Corvatta, M. Marconi, L. Malerba, A. Olivieri, S. Rupoli, F. Alesiani, P. Leoni (2002)
Gemcitabine Alone or Combined with Cisplatin in Relapsed or Refractory Multiple MyelomaLeukemia & Lymphoma, 43
-
C. Nabhan, N. Krett, V. Gandhi, S. Rosen (2001)
Gemcitabine in hematologic malignanciesCurrent Opinion in Oncology, 13
-
S. Kaye (1994)
Gemcitabine: current status of phase I and II trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 8
- Publisher
- Springer Journals
- Copyright
- Copyright © 2004 by Springer-Verlag
- Subject
- Medicine
- ISSN
- 0344-5704
- eISSN
- 1432-0843
- DOI
- 10.1007/s00280-004-0777-2
- pmid
- 15133625
- Publisher site
- See Article on Publisher Site
Abstract
These results suggest that gemcitabine is a potent nucleoside analog in MM cell lines including cell types resistant to other chemotherapeutic agents. The greater activity of gemcitabine compared to other analogs seems to be due to favorable metabolism of this agent.
Journal
Cancer Chemotherapy and Pharmacology – Springer Journals
Published: Aug 1, 2004